Cargando…

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Einsele, Hermann, Moreau, Philippe, Bahlis, Nizar J, Bhutani, Manisha, Vincent, Laure, Karlin, Lionel, Perrot, Aurore, Goldschmidt, Hartmut, van de Donk, Niels W.C.J., Ocio, Enrique, Martinez-Lopez, Joaquín, Rodríguez-Otero, Paula, Dytfeld, Dominik, Diels, Joris, Strulev, Vadim, Haddad, Imene, Renaud, Thomas, Ammann, Eric, Cabrieto, Jedelyn, Perualila, Nolen, Gan, Ryan, Zhang, Youyi, Parekh, Trilok, Albrecht, Claire, Weisel, Katja, Mateos, Maria-Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430900/ http://dx.doi.org/10.1097/01.HS9.0000970596.51835.28

Ejemplares similares

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Moreau, Philippe, et al.
Publicado: (2023)

P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL-LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2-YEAR FOLLOW-UP
por: Moreau, Philippe, et al.
Publicado: (2023)

P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY
por: Einsele, H., et al.
Publicado: (2022)

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
por: Moreau, Philippe, et al.
Publicado: (2023)

P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Delforge, M., et al.
Publicado: (2022)

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study
por: Oliveira-Maia, Albino J., et al.
Publicado: (2023)

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
por: Oliveira-Maia, Albino J., et al.
Publicado: (2023)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
por: Weisel, K., et al.
Publicado: (2022)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
por: Merz, Maximilian, et al.
Publicado: (2021)

P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Chari, Ajai, et al.
Publicado: (2023)

PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ye, Jing Christine, et al.
Publicado: (2023)

P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS
por: Oriol, Albert, et al.
Publicado: (2023)

Talquetamab: A promising immunotherapy for multiple myeloma
por: Tariq, Amna, et al.
Publicado: (2023)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY
por: Einsele, H., et al.
Publicado: (2022)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
por: Rasche, Leo, et al.
Publicado: (2023)

Testing for the Presence of Correlation Changes in a Multivariate Time Series: A Permutation Based Approach
por: Cabrieto, Jedelyn, et al.
Publicado: (2018)

Detecting long-lived autodependency changes in a multivariate system via change point detection and regime switching models
por: Cabrieto, Jedelyn, et al.
Publicado: (2018)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Ileosigmoid knotting: A review of 923 cases
por: Atamanalp, Sabri Selcuk, et al.
Publicado: (2022)

Homenaje: Enrique Echeverría, l923-1972 : exposición antológica
Publicado: (1992)

Homenaje: Enrique Echeverría, l923-1972 : exposición antológica.
Publicado: (1992)

Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma
por: Narayan, Neha, et al.
Publicado: (2022)

923. Rapid Emergence of Candida auris in the Chicago Region
por: Kerins, Janna L, et al.
Publicado: (2018)

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
por: Chouaid, Christos, et al.
Publicado: (2023)

Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
por: Feyerabend, Susan, et al.
Publicado: (2019)

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

MON-923 MENIN Gene Mutation: Unity Amidst Diversity
por: Rais, Nadeem M, et al.
Publicado: (2020)

Mobile Mammography in Underserved Populations: Analysis of Outcomes of 3,923 Women
por: Brooks, Sandra E., et al.
Publicado: (2013)

Beam generation and structural optimization of size-selected Au(923) clusters
por: Lu, Siqi, et al.
Publicado: (2020)

Inconstitucionalidad del artículo 923 de la ley federal del trabajo.
por: Priego Ramírez, Ramiro
Publicado: (1990)

923. Long-term Mortality after Histoplasma Infection in People Living with HIV
por: Cherabie, Joseph, et al.
Publicado: (2020)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

SUN-923 Combination Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma
por: de Filette, Jeroen M K, et al.
Publicado: (2020)

Contribution of Coagulase and Its Regulator SaeRS to Lethality of CA-MRSA 923 Bacteremia
por: Liu, Ying, et al.
Publicado: (2021)

923 Lactococcus garvieae infective endocarditis requiring valve replacement: First case in the United States
por: Sharngoe, Calden, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_39kl6r5ugu9rv5ssmgk32tr7f4